23459-38-3

Basic information

• Product Name: cyclopropyl(phenyl)methanamine
• Synonyms: C-Cyclopropyl-C-phenyl-MethylaMinehydrochloride;1-Phenyl-1-cyclopropaneMethylaMine;C-Cyclopropyl-C-phenyl-methylamine
• CAS NO: 23459-38-3
• Molecular Formula: C₁₀H₁₃N
• Molecular Weight: 147.22
• Mol File: 23459-38-3.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 234.7°C at 760 mmHg
• Flash Point: 98.4°C
• Appearance: /
• Density: 1.082g/cm³
• Vapor Pressure: 0.0521mmHg at 25°C
• Refractive Index: 1.6
• Storage Temp.: 2-8°C
• PKA: 9.29±0.10(Predicted)
• CAS DataBase Reference: cyclopropyl(phenyl)methanamine(CAS DataBase Reference)
• NIST Chemistry Reference: cyclopropyl(phenyl)methanamine(23459-38-3)
• EPA Substance Registry System: cyclopropyl(phenyl)methanamine(23459-38-3)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 23459-38-3(Hazardous Substances Data)

Usage

Description

Cyclopropyl(phenyl)methanamine, also known as 1-Cyclopropyl-1-phenylmethanamine, is a derivative of Benzylamine (B224860). It is an organic compound characterized by the presence of a cyclopropane ring and a phenyl group attached to an amine functional group. This unique structure endows cyclopropyl(phenyl)methanamine with specific properties and potential applications in various fields.

Uses

Used in Pharmaceutical Industry:
Cyclopropyl(phenyl)methanamine is used as a reactant in the preparation of diacetylated benzylamide, which has demonstrated potential as an anti-cancer agent. The compound is particularly effective in inducing a G1/G0 arrest in tumor cells, which can help prevent the uncontrolled growth and proliferation of cancer cells. Additionally, it has shown cytotoxicity against human ovarian cancer cells, making it a promising candidate for the development of novel cancer treatments.
Used in Chemical Synthesis:
As a derivative of Benzylamine, cyclopropyl(phenyl)methanamine can be utilized as a building block or intermediate in the synthesis of various organic compounds. Its unique structure allows for further functionalization and modification, enabling the creation of a wide range of molecules with diverse applications in the chemical, pharmaceutical, and materials science industries.

InChI:InChI=1/C10H13N/c11-10(9-6-7-9)8-4-2-1-3-5-8/h1-5,9-10H,6-7,11H2

Upstream product

• 23719-80-4 cyclopropylmagnesium bromide 
• 100-47-0 benzonitrile 
• 4333-56-6 cyclopropyl bromide 
• 3481-02-5 cyclopropyl phenyl ketone 
• 64-17-5 ethanol 
• 7555-72-8 cyclopropyl(phenyl)methanone oxime 

Downstream Products

• 74787-86-3 3-(Cyclopropyl-phenyl-methyl)-1-(2-hydroxy-ethyl)-1-methyl-thiourea 
• 1001088-68-1 (E)-3-(4-chloro-3-nitrophenyl)-2-cyano-N-(cyclopropyl(phenyl)methyl)acrylamide 
• 1001088-69-2 (E)-2-cyano-N-(cyclopropyl(phenyl)methyl)-3-(3-nitro-4-(piperidin-1-yl)phenyl)acrylamide 
• 1001088-70-5 (E)-2-cyano-N-(cyclopropyl(phenyl)methyl)-3-(4-hexylphenyl)acrylamide 
• 1001088-71-6 (E)-2-cyano-N-(cyclopropyl(phenyl)methyl)-3-(5-(3-nitrophenyl)furan-2-yl)acrylamide 
• 1338793-54-6 N-(cyclopropyl(phenyl)methyl)-3-(3-sulfamoylphenyl)-1H-indazole-5-carboxamide 
• 1376352-76-9 C₁₃H₁₉NO₃S 
• 1376332-88-5 N-(cyclopropylphenylmethyl)methanesulfonamide 
• 1376394-94-3 C₁₇H₂₅NO₂S 
• 73611-78-6 (Z)-(4-bromobut-1-en-1-yl)benzene 

Relevant articles and documents

A JAK/STAT3 phosphorylation inhibitor and its preparation method and use thereof

The invention provides a JAK/STAT3 phosphorylation inhibitor as well as a preparation method and application thereof. The structural formula of the JAK/STAT3 phosphorylation inhibitor is as shown in a formula I, wherein X is selected from S or O; Y and Z

Influence of bulky substituents on histamine H3 receptor agonist/antagonist properties

Novel derivatives of 3-(1H-imidazol-4-yl)propanol were designed on the basis of lead compounds belonging to the carbamate or ether series possessing (partial) agonist properties on screening assays of the histamine H3 receptor. One pair of enantiomers in the series of α-methyl-branched chiral carbamates was stereoselectively prepared in high optical yields. Enantiomeric purity was checked by Mosher amide derivatives of precursors and capillary electrophoresis of the final compounds with trimethyl-β-cyclodextrin as chiral selector, and was determined to be ≥95%. The novel compounds were investigated in various histamine H3 receptor assays in vitro and in vivo. Some compounds displayed partial agonist activity on synaptosomes of rat brain cortex, whereas others exhibited antagonist properties only. Selected compounds were investigated in [125I]iodoproxyfan binding studies on the human histamine H3 receptor and showed high affinity in the nanomolar concentration range. Under in vivo conditions after oral administration to mice, some of the compounds exhibited partial or full agonist activity in the brain at low dosages. The (S)-enantiomer of one pair of chiral carbamates (9) proved to be the eutomer; thus, the (S)-enantiomer was selected for further pharmacological studies. In a peripheral in vivo test model in rats, measuring the level of inhibition of capsaicin-induced plasma extravasation, (S)-9 again proved its high oral agonist potency with full intrinsic activity (ED50 values of 0.07-0.1 mg/kg depending on tissue).

Hypoglycemic α cycloalkylphenylmethyl, furanalkyl, and thiophenealkyl lactamimides

A series of α cycloalkylphenylmethyl lactamimides and a series of furan and thiophenealkyl lactamimides were prepared for biological evaluation as an extension of earlier findings of hypoglycemic activity in lactamimides. Several compounds produced pronouced hypoglycemia after oral administration to fasted, glucose primed rats.